PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors | Journal for ImmunoTherapy of Cancer | Full Text
JCI - Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy | Science Advances
Frontiers | Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update
Definition of immune checkpoint inhibitor - NCI Dictionary of Cancer Terms - NCI
Development of domain-specific PD-L1 antibodies a-b, To assess PD-L1... | Download Scientific Diagram
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy - ScienceDirect
Antibody Engineering | Review | InvivoGen
Each blocking antibody for PD-1, PD-L1, or PD-L2 requires its own... | Download Scientific Diagram
PD-1 PD-L1 Blockade Bioassay | PD1 PDL1 | PD1 PDL1 Interactions
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1 | Journal for ImmunoTherapy of Cancer
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy | Journal of the American Chemical Society
PD-1/PD-L1 immune checkpoint Bioassay - Cellomatics Biosciences
TLR4 signaling improves PD-1 blockade therapy during chronic viral infection | PLOS Pathogens
Advertorial: Novel Bioassay to Assess PD-1/PD-L1 Therapeutic Antibodies in Development for Immunotherapy
PD1 Antibody Selection Tool | Bio X Cell
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function | PLOS ONE
Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody - RSC Advances (RSC Publishing)
Screening Inhibitors that Target PD-1/PD-L1 Binding using AlphaLISA
